Steris Healthcare: Committed to Quality Healthcare and Pharmaceutical Excellence

 Raloxifene Hydrochloride Tablets IP 60 mg (REXFARM 60) — Uses, Benefits, Dosage & Side Effects

Raloxifene Hydrochloride Tablets IP 60 mg belongs to a class of medications known as selective estrogen receptor modulators, which act like estrogen in some tissues while blocking its effects in others — offering the bone-protective benefits of estrogen without stimulating estrogen-sensitive tissues elsewhere in the body. Raloxifene Hydrochloride 60mg tablets are commonly used to help prevent and treat osteoporosis in postmenopausal women, working by mimicking estrogen's effects on bone density and thereby reducing the risk of fractures. REXFARM 60 is particularly valuable for postmenopausal women who cannot tolerate traditional hormone replacement therapy, offering a tissue-selective alternative that specifically targets bone health. 

Why It's Important

Osteoporosis is a silent but serious condition that affects a significant proportion of postmenopausal women, as declining estrogen levels accelerate bone density loss, increasing the risk of fractures — particularly of the hip, spine, and wrist. These fractures can severely compromise mobility, independence, and quality of life, and in older patients, hip fractures in particular carry substantial morbidity and mortality risk. Managing this bone loss proactively is essential, yet many women are unable to use conventional estrogen therapy due to contraindications or personal risk factors, such as a history of hormone-sensitive conditions. Raloxifene Hydrochloride is often prescribed for women who cannot tolerate estrogen therapy, making REXFARM 60 an important therapeutic option that fills this treatment gap. Additionally, some healthcare providers may prescribe it to lower the risk of invasive breast cancer in high-risk postmenopausal patients, extending its clinical relevance beyond bone health alone. 

Key Benefits of REXFARM 60

What Are the Benefits of This Combination?

• Reduces fracture risk — slows down bone loss and helps keep bones strong, making them less likely to break 
• Estrogen-like bone protection without systemic estrogen exposure — offers targeted action on bone tissue while avoiding stimulation of breast or uterine tissue
• Suitable alternative to hormone replacement therapy — particularly useful for women who cannot or prefer not to use estrogen-based treatments
• Potential breast cancer risk reduction — may help lower the risk of invasive breast cancer in certain high-risk postmenopausal women 
• Supports long-term skeletal stability — helps maintain bone strength and reduce bone loss over time, supporting daily comfort and mobility 
• Well-studied, established therapeutic profile — decades of clinical use in postmenopausal bone health management

Side Effects

REXFARM 60 is generally well tolerated, but as with any medication, some patients may experience side effects, including:

• Hot flashes, leg cramps, and swelling in the legs or feet 
• Flu-like symptoms, joint pain, or headache 
• Mild nausea
• Sweating

Serious Side Effects 

Patients should seek immediate medical attention if they experience:

• Signs of blood clots, such as sudden leg pain, swelling, warmth, or redness in one leg (deep vein thrombosis)
• Sudden shortness of breath, chest pain, or coughing up blood (signs of a pulmonary embolism)
• Sudden vision changes, severe headache, or slurred speech (possible signs of stroke)
• Signs of liver dysfunction, such as yellowing of the skin or eyes, dark urine, or persistent nausea
• Unusual vaginal bleeding

Available Substitutes 

Raloxiheal 60, manufactured by Healing Pharma, is a widely available comparable brand containing the same 60mg Raloxifene Hydrochloride composition, commonly used to treat osteoporosis. Several other regional and generic formulations of Raloxifene Hydrochloride 60mg are also available through pharmaceutical distributors and PCD channels across India. Patients should not switch between Raloxifene brands without consulting their physician, as consistent dosing and monitoring are important for long-term bone health management. 

Dosage Guidelines 

The typical recommended dosage is one tablet (60mg) once daily, which may be taken at any time of day, with or without food. Treatment duration for osteoporosis prevention and management is generally long-term and should be guided by regular bone density monitoring and periodic physician review. Adequate calcium and Vitamin D intake is usually recommended alongside Raloxifene therapy to support optimal bone health outcomes, as advised by the treating physician.

Precautions & Warnings

• Should be used with caution in individuals with a history of blood clots or liver disease 
• Inform your healthcare provider about any history of blood clots, stroke, or liver issues before starting this medication 
• Not recommended for use in premenopausal women or in women who could become pregnant, as it is intended solely for postmenopausal use
• Discontinue use and consult a doctor immediately if symptoms of blood clot formation occur
• Should be temporarily discontinued before prolonged immobilization, such as extended bed rest or major surgery, due to increased clotting risk
• Not intended for use as a pain reliever — it works to support long-term bone density rather than provide immediate symptomatic relief
• Store at room temperature away from moisture and heat 
• Inform your doctor of all other medications being taken to avoid potential drug interactions

Mechanism of Action

Raloxifene Hydrochloride functions as a selective estrogen receptor modulator (SERM), meaning it interacts with estrogen receptors differently depending on the target tissue. It works by blocking estrogen activity in breast tissue while mimicking estrogen's beneficial effects in bone. In bone tissue, Raloxifene binds to estrogen receptors and activates pathways that reduce bone resorption (breakdown) by osteoclasts, helping preserve bone mineral density and reduce fracture risk — effectively replicating estrogen's protective skeletal effects. Simultaneously, in breast and uterine tissue, Raloxifene acts as an estrogen antagonist, blocking estrogen receptor activation in these tissues, which is believed to underlie its potential role in reducing the risk of estrogen-receptor-positive invasive breast cancer, without the increased risk of endometrial stimulation associated with traditional estrogen therapy. This tissue-selective dual action is what distinguishes SERMs like Raloxifene from conventional hormone replacement therapy. 

Conclusion

REXFARM 60 by Steris Healthcare offers postmenopausal women a clinically established, tissue-selective approach to managing osteoporosis risk, combining the bone-protective benefits of estrogen-like activity with a favorable safety profile for breast and uterine tissue. For women who cannot use traditional hormone replacement therapy or who fall into a higher breast cancer risk category, REXFARM 60 represents a valuable, well-studied therapeutic option — best used as part of a comprehensive bone health plan that includes adequate calcium, Vitamin D, weight-bearing exercise, and regular medical follow-up.